Zealand Pharma (CPH: ZEAL) net income
Zealand Pharma reported a net profit of DKK 6,455m for fiscal 2025; in fiscal 2024 it reported a net loss of DKK 1,079m. Its net margin was 70.0%. Earnings per share were DKK 91.56.
Fiscal 2025 is the highest of the 7 fiscal years on record for Zealand Pharma. It reported a loss in 6 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | DKK 6,455m | — | 70.0% | DKK 91.56 |
| 2024 | −DKK 1,079m | — | −1,720.9% | −DKK 16.24 |
| 2023 | −DKK 703.7m | — | −205.3% | −DKK 12.44 |
| 2022 | −DKK 1,202m | — | −1,156.1% | −DKK 26.02 |
| 2021 | −DKK 1,018m | — | −938.0% | −DKK 23.75 |
| 2020 | −DKK 846.7m | — | −239.7% | −DKK 22.07 |
| 2019 | −DKK 571.5m | — | −1,382.8% | −DKK 16.91 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of Danish kroner, except per-share amounts.
Zealand Pharma net income compared with its sector
By net income for its latest fiscal year, Zealand Pharma ranks 9th of the 65 Spanish and European health care companies with a page on Celsmar. The sector median net margin is 5.8%; that of Zealand Pharma, 70.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 7th | Philips | €895.0m | 5.0% |
| 8th | Genmab | $963.0m | 25.9% |
| 9th | Zealand Pharma | DKK 6,455m | 70.0% |
| 10th | Smith & Nephew | $625.0m | 10.1% |
| 11th | Orion | €500.3m | 26.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in health care stocks.
Questions about the net income of Zealand Pharma
- How much did Zealand Pharma earn in fiscal 2025?
- Zealand Pharma reported a net profit of DKK 6,455m for fiscal 2025. In fiscal 2024 it reported a net loss of DKK 1,079m.
- What are the earnings per share of Zealand Pharma?
- They were DKK 91.56 in fiscal 2025, compared with −DKK 16.24 in fiscal 2024.
- What is the net margin of Zealand Pharma?
- In fiscal 2025 its net profit was 70.0% of its revenue.
- What was the most profitable year for Zealand Pharma?
- Of its last 7 fiscal years, fiscal 2025, with DKK 6,455m.
- Where does Zealand Pharma rank in its sector by net income?
- It ranks 9th of the 65 Spanish and European health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Zealand Pharma come from?
- From the report Zealand Pharma files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Zealand Pharma files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2020. More on Zealand Pharma: the Zealand Pharma page · annual accounts · revenue.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.